Henry Schien To Distribute Grifols Product In United States
Zacks Investment Research | Mar 05, 2018 09:42PM ET
Henry Schein, Inc.’s (NASDAQ:HSIC) latest deal with Grifols (NASDAQ:GRFS) adds stimulus to its distribution business. Both companies have signed a distribution agreement, enabling the former to market and distribute the latter's 500mL Normal Saline solution (0.9% Sodium Chloride Injection, USP) in U.S. market.
Notably, Grifols is a leading producer of plasma-derived medicines and a forerunner in the research and development of therapeutic alternatives. The company manufactures this 500mL Normal Saline solution at its industrial complex in Murcia (Spain) and received the FDA approval to market the product in the United States Only last year.
With growing demand for saline products in the U.S. market, we believe this partnership will be strategically beneficial for Henry Schein. Per the company, this solution by Grifols has capacity to quickly meet its customers' needs during the shortage of IV solutions.Both companies can gain an impetus from the global supply infrastructure as well as Henry Schein’s widespread network.
In this regard, we note that Henry Schein’s distribution business boasts a broad global footprint with 61 distribution centers located all over. Apart from North America and Europe, the company has presence across Australia and New Zealand as well as in the emerging markets like China, Brazil, Israel, Czech Republic and Poland being the latest target hub.
Grifols apart, the company’s significant distribution partners are Terason and DENTSPLY SIRONA. While Henry Schein exclusively distributes Terason’s uSmart 3200T NexGen, its Canadian dental subsidiary distributes the entire DENTSPLY SIRONA product line.
Share Price Movement
Over the past three months, shares of Henry Schein have underperformed the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.